| Detailed information |
|---|
| CancerLivER ID | 2359 |
| Biomarker | RhoC |
| Biomarker Name/Symbol (given in Publication) | RhoC |
| Biomolecule | Protein and RNA |
| Subject | Human |
| Degree of Validity | RhoC expression could be used as a potential prognostic marker for HCC (correlates with a poor prognosis of HCC); but not validated on independent dataset |
| Experimental Condition | EHML (Extrahepatic Metastatic Lesions) v/s HCC and PCLT(pericarcinomatous liver tissues); increased RhoC expression strongly correlates with vein invasion |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in highly invasive NHCC than in less invasive SLHCC and upregulated in EHML (Extrahepatic Metastatic Lesions) than HCC and PCLT (Pericarcinomatous liver tissues). |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 15150600 |
| Type of Biomarker | Prognostic |
| Pathway | organization of the actin cytoskeleton and regulate cell shape, attachment, and motility |
| Cohort | 25 HCC patients: (7 SLHCC (solitary large hepatocellular carcinoma; with diameter >5cm); 15NHCC (nodular hepatocellular carcinoma with node number >2); 3 SHCC (small hepatocellular carcinoma with diameter < 5cm)); |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | EHML (Extrahepatic Metastatic Lesions) v/s HCC and PCLT |
| Year of Publication | 2004 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |